報價延遲最少15分鐘:2025/01/11 11:15 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.4124 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.86/-2.76
|
|
企業價值
13.64M
|
| 資產負債 |
|
每股賬面淨值
1.58
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 11:15 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment ofdepression and other potential indications. |